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Abstract The availability of analytical methods to detect
and determine levels of markers of priority allergens in
foods is of the utmost importance to support standard
setting initiatives, the development of compliance and
enforcement activities, as well as to provide guidance to
industry on implementation of quality control practices,
ensuring the effectiveness of allergen-related sanitation
techniques. This paper describes the development and
implementation of a mass-spectrometry-based technique to
determine markers for individual sources of gluten in beer
products. This methodology was shown to answer the
requirements of Health Canada’s proposed labeling standard
for individual gluten source declaration, in order to achieve
its policy objectives (i.e., protection of sensitive consumers,
while promoting choice). Minimal sample work-up was
required and the results obtained by ELISA were further
complemented using the LC-MS/MS method. This paper
aims to demonstrate the feasibility of alternative techniques
to ELISA-based methodologies to determine allergen and
gluten markers in food.
Keywords Immunoassays.ELISA.Bioanalytical
methods.Foods.Beverages.Massspectrometry
Introduction to celiac disease
Celiac disease (CD) is an immune mediated disease,
triggered in genetically susceptible individuals by the
ingestion of gluten. It is also known as celiac sprue or
gluten-sensitive enteropathy. Individuals with CD and
dermatitis herpetiformis, a related skin condition, react
adversely to the specific proteins of wheat, rye, and barley
which are categorized as gluten. Gluten is a generic name
given to storage proteins in wheat, barley, rye, and other
closely related cereal grains. Prolamins are the aqueous
alcohol soluble fraction of gluten isolated from these grains
and their hybridized strains (i.e., triticale). In those
individuals with CD, these proteins trigger an inflammatory
injury in the absorptive surface of the small intestine
resulting in malabsorption of protein, fat, carbohydrate,
fat-soluble vitamins, folate, and minerals, especially iron
and calcium [1–4].
For individuals with CD, exposure to gluten can result in
the deterioration, over time, of the cell lining of the small
intestine. It is a lifelong condition, and if it is not diagnosed
early and treated with a strict gluten-free diet, it can be
associated with serious complications, including osteopo-
rosis, lymphoma, and other types of malignancies, infertil-
ity in both men and women and a number of autoimmune
diseases including insulin dependent diabetes in children.
Moreover, in children, CD can be associated with failure to
grow and delayed puberty [2–4]. But beyond the health
impacts described above, other impacts such as their effects
on quality of life family and social circle are yet to be
determined and better understood.
The symptoms and associated conditions of CD vary
greatly in number and severity resulting in frequent delays
in diagnosis, and misdiagnoses such as irritable bowel
syndrome, chronic fatigue syndrome, and fibromyalgia are
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DOI 10.1007/s00216-009-2943-1common. A small intestinal biopsy is necessary to confirm
the diagnosis. With the advent of new blood tests, the
worldwide prevalence of the disease is now estimated to be
between 1/100 and 1/200. Certain groups have markedly
elevated risks of CD. First-degree relatives of individuals
diagnosed with CD have a 10% to 20% risk of developing
CD. A high prevalence is also found in those with Down
syndrome. Patients with CD have an increased risk of
association with other serious conditions such as Type I
diabetes mellitus and other autoimmune disorders [1, 5, 6].
Although CD is not an IgE-mediated reaction, it fits the
general definition of food allergies, which includes all
adverse reactions to food, involving an immune mecha-
nism, both IgE-mediated and non-IgE-mediated.
Risk management options for people with celiac disease:
avoidance of gluten-containing ingredients, through
properly labeled foods
There are currently no known therapeutic options to cure
celiac disease, but rather to treat and manage symptoms.
The only viable option for celiac disease sufferers is to
prevent such symptoms from occurring by avoiding
gluten-containing foods. In fact, a strict lifelong avoid-
ance of gluten in the diet is the only effective
management of this disease and for the prevention of
subsequent complications [1].
In avoiding foods containing the culprit ingredients to
which they are likely to react, celiac individuals and wheat
allergy suffers must rely on information provided to them
by food processors and importers. For prepackaged foods, it
is critical that presence of ingredients, specifically those
derived from cereals such as wheat, barley, rye, or oats be
clearly indicated on the label. Similarly, if the foods are
prepared in a manner that makes them suitable for celiac
individuals, by excluding wheat, barley, and rye proteins,
they could be identified as “Gluten-free” to make them
easily identifiable by consumers who seek them. Under
these conditions, labeling is identified as a public health
tool enabling susceptible consumers to manage avoidance,
but also allowing informed choice from safe and nutritious
food sources.
Regulatory requirements for labeling of gluten
in prepackaged foods available for sale in Canada
Labeling of prepackaged foods for gluten sources and the
identification of “Gluten-free” foods through labeling has
been the focus of various labeling regulations and legis-
lations throughout the world, as a tool to help manage
celiac disease.
The Codex Committee on Nutrition and Foods for
Special Dietary Uses (CCNFSDU) has been engaged in
the development of international standards defining gluten
free foods. The latest standard was adopted by the Codex
Alimentarius Commission at its last meeting in 2008
(CODEX STAN 118-1979—amended in 1983 and revised
in 2008) and defines gluten free foods as foods containing
less than 20 ppm of proteins derived from wheat, barley,
rye and/or any of their hybridized strains.
In Canada, Health Canada has the mandate to establish
food standards, policies, regulations, and guidelines. The
department has oversight on labeling requirements associ-
ated with health and safety or nutritional quality concerns.
The Canadian Food Inspection Agency (CFIA) is respon-
sible for“…the enforcement oftheFood and Drugs Act as it
relates to food, as defined in section 2 of that Act…”,i n
other words “for…any article manufactured, sold, or
represented for use as food or drink for human beings.”
A proposed regulatory amendment has recently been
developed and published[7], which introduces a regulatory
definition for gluten as «any gluten protein from the grain
of any of the following cereals or the grain of a hybridized
strain created from at least one of the following cereals:»
& Wheat, spelt, kamut
& Oats
& Barley
& Rye
& Triticale
This regulatory proposal would impose the declaration
of any gluten sources (i.e. the cereal) on the food label of
processed foods available for sale in Canada, when gluten
(as defined by the regulation) is present in the food, as a
result of deliberate addition (as an ingredient entering in the
composition of the product). This proposal is currently
subject to public comments, with its final version planned
for implementation in early 2010.
Similarly, Canadian food regulators have been amongst
the pioneering regulators to introduce a “Gluten-Free”
regulation. Division 24 of the Canadian Food and Drug
Regulations (food for specialty dietary purposes) has
defined gluten-free products (B24.018). The requirements
for a gluten free product according to these regulations are
as follows: «No person shall label, package, sell, or
advertise a food in a manner likely to create an impression
that it is a gluten free food unless the food does not contain
wheat, including spelt and kamut, or oats, barley, rye or
triticale or any part thereof». This regulation was enacted in
1996 and enabled the availability of gluten-free foods for
celiac and wheat allergic individuals. This regulation did
not include a threshold for compliance and its enforcement
was based on the analytical threshold of the time (i.e.
200 ppm of gluten as detected by enzyme-linked immuno-
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late 1990s). With the development and availability of more
sensitive techniques, this threshold was lowered to 20 ppm.
This 20-ppm gluten level is based on clinical and
serological evidence that chronic exposure of traces of
gluten traces in the diet does not cause inflammation of
small intestine mucosa or change in small intestinal
architecture, and at the same time allowing a margin of
safety for the variable gluten sensitivity and dietary habits
of the celiac [8]. The gluten-free regulation imposes that
manufacturers of gluten-free foods ensure that all ingredients
in the gluten free foods comply with the requirements set in
the regulations. They must ensure that cross-contamination
in the production facility is prevented, particularly when
gluten-containing foods are handled. The application of this
regulation extends beyond manufacturing conditions to cover
merchandising outlets (wholesale and retail), which must
also ensure that gluten free products are handled in a manner
that enables them to remain gluten-free.
In view of the adoption of the revised gluten free
standard by the Codex Alimentarius Commission (CODEX
STAN 118-1979—amended in 1983 and revised in 2008),
Health Canada is currently reviewing the gluten-free
regulations to further align with its proposed regulatory
amendments for labeling of allergens, gluten sources, and
added sulfites. Current considerations include the use of the
same definition for gluten, where the presence of the
protein fraction derived from cereal ingredients would be
required to trigger the exclusion of the food from bearing
the label of “gluten free”. Such consideration will allow
products to make a gluten-free claim, even though they
contain an ingredient deriving from the incriminated cereal,
as long as the protein fraction has been removed and is not
present. For example, products containing maltodextrin or
other sugar-based ingredients deriving from cereals will be
able to bear a “Gluten free” claim, therefore enabling more
choice. Considerations are also being made for the removal
of oats from the list of excluded cereals, while specific
requirements are developed for “Gluten-free oats”, being
defined as free from protein derived from the other cereals
such as wheat, rye, or barley [9].
Introduction of new labeling requirements for gluten
sources—need for analytical methods
The availability of analytical methods to detect and
determine levels of markers of priority allergens in foods
is of the utmost importance to support standard setting
initiatives, the development of compliance and enforcement
activities, as well as to provide guidance to industry on
implementation of quality control practices, ensuring the
effectiveness of allergen-related sanitation techniques. In
the early 1990s, Health Canada’s Food Program launched
an ambitious allergen method development program.
Methods were developed for the detection of peanut [10,
11], egg [12], hazelnut [13], and crustacean tropomyosin
[14]. After the creation of the Canadian Food Inspection
Agency (CFIA) in 1997, these methods were transferred to
the agency’s laboratories and made the backbone of the
laboratory capacity in support of the Canadian compliance
programs with regards to undeclared allergens in processed
foods. Since that time, a number of commercially available
allergen test kits have emerged, enabling the determination
of markers of priority allergens in a variety of foods. These
kits are either based on the immunochemical or PCR
approaches, and have become more widely available for an
increasing number of different allergens.
While maintaining its capacity for method development
and validation, Health Canada’s food allergen methodology
program has been realigned to support regulation making
and standard setting.
As a food regulator, Health Canada’s Food Directorate
may be challenged about the availability of methodologies
to support its proposed regulatory measures and standards
associated with labeling of allergen and gluten sources.
In fact, the regulated food industry is to expect from
food regulators to be open and transparent about analytical
methods, which are meant to support compliance measures.
They are also to expect that such methods be available to
demonstrate the feasibility of food standards under devel-
opment and the ability to comply with them. Health Canada
was therefore asked by some food stakeholders' guidance
on analytical methods that support its proposed labeling
standard to declare sources of gluten in food products such
as alcoholic beverages and in particular, beer.
Gluten protein in beer products
Gluten is a class of proteins found in wheat, barley, rye, and
other grains. It includes the two groups of proteins known
as glutelins and prolamins. Glutelins consist of the low-
molecular-weight glutenins and the high-molecular-weight
glutenins with masses ranging from 15 to 150 kDa. These
proteins contain an abundance of cysteine residues resulting
in an increase of intra- and intermolecular disulfide
bonding, hence their high molecular weight. When reduced,
these glutelins yield subunits of lower molecular masses.
The prolamins are monomeric polypeptide chains with
molecular weights between 30 to 50 kDa. They are rich in
proline and glutamine (20–55%). Prolamins in wheat are
known as gliadins, in barley as hordeins, in oats as avenins,
and in rye as secalins. Celiac individuals may also react not
only towards gliadins but also towards barley gluten
(hordein) and rye gluten (secalin).
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sources of gluten are meant to enable celiac individuals to
identify those foods containing gluten sources, but also to
allow those with wheat allergy to clearly distinguish wheat-
containing foods from foods where other gluten sources
were used as ingredients. This measure would enable to
protect sensitive consumers (both celiacs and individuals
with wheat allergy), while promoting their food choices.
Beer products will be subject to Health Canada’s
proposed measures for declaration of gluten sources. Some
stakeholders requested guidance as to the availability of
methods to determine markers of gluten in beverages such
as beer, given that bioanalytical techniques based on ELISA
may not be providing determining results whose purpose is,
in particular, to clearly identify the source of gluten. The
purpose of this paper is to summarize recent progress
accomplished by Health Canada’s Food Allergen Research
Program in enabling determination and confirmation of
gluten protein markers in beverages such as beer products
using a combination of protein separation techniques
coupled with mass spectrometry.
Since most beers are brewed from barley malt, residual
barley proteins, hordein in particular, are expected to be
present. Depending on the type of beer however, other
gluten protein markers would be more prevalent.
Materials and method
A method was specifically developed to address the
extraction and identification of markers of gluten from beer
products.
A minimal sample work-up protocol was used to prepare
the sample. An aliquot of degassed beer sample was diluted
five to ten times with the extraction solvent ethanol/water
(60:40). The solution was vortexed for 30 s and then
centrifuged at 11,000 rpm for 30 min. A 30-µL aliquot of
the supernatant was digested with trypsin at 37 °C for 6 h,
after reduction with dithiothreitol (DTT) and alkylation
with iodoacetamide (IA). The tryptic digest was analyzed
by capillary liquid chromatography–tandem mass spectros-
copy (LC-MS/MS) using Water’s CapLC/QTOF2 system.
Instrumentation
The LC-MS/MS system used was a Waters CapLC system
coupled to a Waters quadrupole-time of flight mass
spectrometer (QTOF2) with nanolockspray (Waters, Mil-
ford, MA). Detailed experimental parameters were de-
scribed in our previous work on the mass-spectrometric
detection of milk allergens [15].
LC conditions
Tryptic digests of beer samples were analyzed using a
combination of a pre-column (OPTI-PAK 0.35 mm×5 mm
packed with Waters Symmetry 300 C18 5 µm [Waters,
Milford, MA]) and an analytical column. Two types of
analytical columns were used: traditional 3–5-µm C18
particulate nano columns (100 mm×75 µm packed with
5 µm PepMap C18 100 Å [LC Packing/Dionex, Sunnyvale,
CA]) and monolithic columns ([0.1 mm×150 mm] silica
monolithic column Onyx C18 [Phenomenex, Torrance,
CA]). The LC gradient was carried out with 0.1% formic
acid in acetonitrile:water (3:97; v:v) as solvent A and 0.1%
formic acid in acetonitrile as solvent B programmed from
5%B to 35%B in 45 min. at approx. 200 nL/min flow.
Mass spectrometry conditions
The mass spectrometer was operated in nanospray ESI+
mode at a resolution of 10,000 with nanolockspray for
accurate mass correction (mass error <5 ppm). The capillary
voltage was set at 3.5 kVand cone voltage at 45 V. The data
acquisition was performed using Masslynx 4.0 in survey
(DDA—data-directed analysis) mode with MS to MS/MS
criteria based on charge state selection (+2, +3, and +4).
Data analysis
Three bioinformatic suites were used to analyze the data
obtained from the LC-MS/MS process: Proteinlynx Global
Server v2.3 (PLGS, Waters, Milford, MA), Mascot (which
includes Mascot Distiller, Mascot Deamon, and Mascot
Server, a bioinformatics software package from Matrix
Science (Matrix Science Inc., Boston, MA)) and Peaks
Studio v 4.5 (BSI Bioinformatics Solutions Inc., Waterloo,
Ontario). Each package contains its own peak detection
software which processesthe raw DDA datainto de-isotoped
peak lists. These precursor ions list with their corresponding
MS/MS spectra were then submitted to a database search for
protein identification based on the peptides found.
ELISA method
A commercial ELISA for gluten determination was used to
test beer samples and compare results with those generated
by mass spectrometry. Test kits were purchased from R-
Biopharm Inc. MI, USA. The ELISA enabled the determi-
nation of gluten protein with a detection level as low as 3
parts per million and with a cross-reactivity to proteins
derived from wheat, rye, and barley. Sample extraction and
handling followed the manufacturer’s instructions
114 D. Weber et al.Table 1 Major proteins identified in the beer digest based on the proteomic approach using mass-spectrometric techniques (criteria for protein
detection based on the Mascot score being above the significant hit threshold with three or more peptides matched to the protein)
Sample Accession Protein name
B08 gi|47168353 Chain A, Non-Specific Lipid Transfer Protein 1 From Barley
gi|108597921 Dimeric alpha-amylase inhibitor precursor [Triticum aestivum]
gi|89143120 Putative avenin-like a precursor [Triticum aestivum]
gi|84617213 Type 2 non-specific lipid transfer protein precursor [Triticum aestivum]
gi|164457873 High-molecular-weight glutenin subunit y10 [Triticum aestivum]
gi|17425212 Low-molecular-weight glutenin subunit group 10 type V [Triticum aestivum]
gi|10638433 Gamma-gliadin [Triticum turgidum]
gi|7209265 Alpha-gliadin [Triticum aestivum]
B11 gi|19039 LTP 1 [Hordeum vulgare]
gi|123970 Alpha-amylase inhibitor BDAI-1 precursor [Hordeum vulgare]
gi|30421167 D-Hordein [Hordeum vulgare]
gi|225102 Trypsin/amylase inhibitor pUP13 [Hordeum vulgare]
gi|288709 Gamma 3 hordein [Hordeum vulgare]
gi|19079 Protein Z (180 AA) [Hordeum vulgare]
gi|18929 B hordein precursor [Hordeum vulgare]
B16 gi|19039 LTP 1 [Hordeum vulgare]
gi|585291 Alpha-amylase/trypsin inhibitor CMd precursor [Hordeum vulgare]
gi|1310677 Protein z-type serpin [Hordeum vulgare]
gi|226755 Gamma-hordein [Hordeum vulgare]
gi|30421167 D-Hordein [Hordeum vulgare]
gi|224385 hordein B [Hordeum vulgare]
gi|288709 Gamma 3 hordein [Hordeum vulgare]
2B01 gi|47168353 Chain A, Non-Specific Lipid Transfer Protein 1 From Barley
gi|1310677 Protein z-type serpin [Hordeum vulgare]
gi|585291 Alpha-amylase/trypsin inhibitor CMd precursor [Hordeum vulgare]
gi|30421167 D-Hordein [Hordeum vulgare]
gi|226755 Gamma-hordein [Hordeum vulgare]
gi|224386 Hordein B [Hordeum vulgare]
gi|288709 Gamma 3 hordein [Hordeum vulgare]
2B07 gi|123970 Alpha-amylase inhibitor BDAI-1 precursor [Hordeum vulgare]
gi|19039 LTP 1 [Hordeum vulgare]
gi|1310677 Protein z-type serpin [Hordeum vulgare]
gi|30421167 D-Hordein [Hordeum vulgare]
gi|226755 Gamma-hordein [Hordeum vulgare]
gi|62484809 Putative gamma-gliadin [Triticum aestivum]
gi|288709 Gamma 3 hordein [Hordeum vulgare]
B15 gi|1310677 Protein z-type serpin [Hordeum vulgare]
gi|19039 LTP 1 [Hordeum vulgare]
gi|226755 Gamma-hordein [Hordeum vulgare]
gi|75282567 Serpin-Z7 [Hordeum vulgare]
2B05 gi|1310677 Protein z-type serpin [Hordeum vulgare]
gi|19039 LTP 1 [Hordeum vulgare]
gi|30421167 D-Hordein [Hordeum vulgare]
gi|123970 Alpha-amylase inhibitor BDAI-1 precursor [Hordeum vulgare]
gi|226755 Gamma-hordein [Hordeum vulgare]
gi|123459 B3-hordein [Hordeum vulgare]
gi|288709 Gamma 3 hordein [Hordeum vulgare]
B17 gi|20159 19 kDa globulin precursor [Oryza sativa]
Analytical methods to determine gluten markers in processed foods 115Results and discussion
Eight different beer products purchased from local liquor
stores, in Ottawa, Ontario (Canada) were analyzed by LC-
MS/MS after digestion with trypsin. The data was pro-
cessed with the bioinformatics suite from Matrix Science.
NCBInr, a non-redundant database of protein sequences
from the National Center for Biotechnology Information,
Bethesda, MD (NCBI) was used in the Mascot MS/MS ion
search. All but one beer showed that the most predominant
proteins present were from barley. Table 1 shows a partial
list of significant hits from the Mascot search. Of all the
beers analyzed, gluten from barley (various homologs of
hordein including B- and D-hordein and gamma-hordein)
were identified in almost all of them. In one of the beers
(B08), alpha-gliadin, gamma-gliadin, high-molecular-
weight (HMW) glutenin and low-molecular-weight glute-
nin, which constitute wheat gluten, were detected. In
addition, other barley proteins such as the lipid transfer
proteins (LTP) and protein z (a major albumin of barley
grain) were found.
Trace amounts of wheat gluten was also found in one of
the beer (2B07) not claimed to be a wheat beer.
One of the beers tested was found to be truly wheat- and
barley-free as claimed on the label and contained mainly
proteins from buckwheat and rice.
These raw data were also analyzed using the other two
bioinformatics suites: PLGS and Peaks Studio. Similar
proteins were identified in all three searches hence
increasing the confidence in the results. Similar results
were obtained using chymotrypsin as the proteolytic
enzyme (data not shown).
Results from LC-MS/MS methods were also compared
with data obtained using ELISA, which is currently the
most common approach for allergen and gluten analysis.
The comparison between results obtained from two types
of methodologies is summarized in Table 2.A se x p e c t e d ,
the wheat beer sample gave a high response with the
gluten-ELISA. Other samples such as B11, B16, 2B01,
and 2B07 also gave a quantifiable response in ELISA
suggesting the presence of gluten. However, the LC-MS/
MS enabled to pinpoint the source of such gluten as barley
gluten. The cross-reactivity observed with the ELISA
method is overcome by the specificity of the MS-based
technique. While samples B15 and 2B05 showed a very
low response with the ELISA, gluten from barley was
formally detected using the LC-MS/MS method. These
beer products would correspond to the category of items
where the gluten source declaration would be most useful.
In fact, these products would be suitable for consumption
to wheat allergic consumers (absence of wheat proteins)
since 76% of wheat allergic consumers only react to wheat
alone [16], while being unfit for consumption for celiac
individuals.
For sample B17, both methods indicated that there is no
gluten, but in addition, the LC-MS/MS method identified
proteins from rice and buckwheat which agrees with the
claim cited on the product label. This confirmation tech-
nique would support the suitability of this type of product to
both celiac individuals and wheat allergic consumers.
Table 1 (continued)
Sample Accession Protein name
gi|20210 Glutelin [Oryza sativa]
gi|29839419 13 S globulin seed storage protein 3 precursor [Fagopyrum esculentum]
gi|83416591 16 kDa allergen [Fagopyrum esculentum]
Table 2 ELISA and LC-MS/MS results for detecting gluten in beer
Sample# Beer type/ Country of origin Gluten-ELISA LC-MS/MS, major proteins ID
B08 Wheat beer/Canada High HMW glutenin (wheat), LTP (wheat), alpha-gliadin (wheat)
B11 Barley beer/Denmark 74 ppm D-hordein, gamma 3 hordein, LTP 1
B16 Barley beer/Canada 22 ppm D-hordein, gamma 3 hordein, LTP 1
2B01 Barley beer/Canada 6 ppm D-hordein, gamma 3 hordein, protein z
2B07 Barley beer/Canada 11 ppm D-hordein, gamma 3 hordein, LTP 1
B15 Barley beer/Mexico Low Gamma-hordein, protein z
2B05 Barley beer/USA Low D-hordein, Gamma-hordein, B3-hordein
B17 Buckwheat beer/Canada nd Glutelin (Oryza sativa), major storage protein (buckwheat)
116 D. Weber et al.Summary and conclusion
Beer products were analyzed using a proteomics approach
based on a mass spectrometry technique to detect and
identify sources of gluten. This methodology was shown to
answer the requirements of Health Canada’s proposed
labeling standard for individual gluten source declaration,
in order to achieve its policy objectives (i.e., protection of
sensitive consumers, while promoting choice). Minimal
sample work-up was required and the results obtained by
ELISA were further complemented using the LC-MS/MS
method.
This paper provides a demonstration of the feasibility of
methods to support enforcement and compliance with the
proposed standard for labeling of gluten sources. It also
shows the feasibility of alternative techniques to ELISA-
based methodologies for confirmation purposes. Current
efforts are underway to enable the use of similar methods
for quantification of gluten protein markers in food.
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